Company Overview
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company dedicated to developing therapeutics for rare cardiovascular conditions, with a specific focus on creating Tecarfarin, a novel oral and reversible anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots. The firm functions within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized developer targeting niche medical needs rather than broad consumer markets. As of the latest data, the company maintains a market capitalization of $11.67M and employs a workforce of 4 individuals to advance its clinical pipeline. The relatively small market cap of $11.67M indicates that Cadrenal Therapeutics is a micro-cap entity with limited public float, while the absence of reported annual revenue figures suggests the company is currently operating in a pre-commercialization phase where cash burn outpaces product sales. This scale reflects the typical characteristics of late-stage biotech firms that prioritize research and development expenditures over immediate profitability, relying on future regulatory approvals and commercialization of their novel anticoagulant to generate substantial revenue streams.
Financial Health
The company reports Net Income (TTM) of $-14,385,641 and EBITDA of $-14,667,773, while Revenue (TTM) is listed as N/A, revealing a financial structure where operating expenses and development costs far exceed any current income generation. The significant gap between the reported revenue and the substantial net loss underscores a cost structure dominated by high burn rates associated with late-stage drug development and clinical trial execution. Free Cash Flow stands at $-6,621,565, indicating that the company is consuming its cash reserves to fund operations and research without generating positive cash flow from commercial activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved commercial scale or that its revenue base is insufficient to calculate meaningful margins in the traditional sense of a mature business. The firm holds Cash of $3.86M and has N/A for total debt, resulting in a Debt to Equity ratio of N/A, which suggests the balance sheet is leveraged through equity dilution rather than traditional debt financing to manage its capital needs. The Current Ratio is 3.02, a figure that indicates the company possesses a conservative short-term liquidity position with assets significantly exceeding its current liabilities, providing a buffer to sustain operations despite the cash burn. Return on Equity is reported at -468.0% and Return on Assets at -209.2%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a common but high-risk characteristic of pre-revenue biotechnology ventures.
Valuation Assessment
The Trailing P/E Ratio (TTM) is N/A due to the lack of positive earnings, while the Forward P/E is -0.92, a metric that implies the market is pricing in future earnings expectations that have not yet been realized or that the stock is trading at a premium relative to anticipated negative earnings. The Price to Book ratio is 3.76, suggesting that the market values the company at a premium of 276% above its book value, which typically reflects the high intrinsic value placed on the company's intellectual property and pipeline potential rather than tangible assets. The Price to Sales ratio is N/A and the EV/EBITDA is -0.44, alternative valuation metrics that suggest the company is being valued on a forward-looking basis or based on intangible assets rather than current cash flow generation or sales multiples. The stock has a 52-Week High of $19.96 and a 52-Week Low of $4.91, placing the current trading price within a wide volatility range that reflects the speculative nature of its asset class. The Beta value of 1.07 indicates that the stock price exhibits slightly higher volatility relative to the broader market, moving 7% more than the market average during periods of fluctuation. These valuation multiples highlight the risks and rewards associated with investing in a company that has not yet crossed the threshold into profitability.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning there is insufficient historical data to calculate growth rates or determine if earnings are growing faster or slower than revenue. Since the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that the firm reinvests all available resources and capital into its research and development activities rather than distributing income to shareholders. The absence of a dividend policy is standard for late-stage biopharmaceutical companies that must retain capital to fund clinical trials and regulatory submissions. The overall growth and income profile is characterized by zero current revenue, zero earnings, and zero dividend payouts, with the company's value entirely dependent on the future success of its Tecarfarin therapeutic in preventing cardiovascular events.